December 12, 2011Date Released: 12 December 2011
CASE CCC IN THE NEWS
UH Seidman Cancer Center Researchers Present Findings at American Society of Hematology Annual Meeting
North Coast Cancer Joins Clinic
Pfizer Kidney Cancer Drug Gets FDA Panel's Nod
Cleveland Clinic Oncologist Recognized for Kidney Cancer Drug Research
Peregrine's Lung Cancer Drug Has Promising Trial
Aplastic Anemia & MDS International Foundation Announces Treating MDS Toolkit, a New Resource for Health Care Providers
Addition to UH Geauga Medical Center to Provide Integrated Cancer Care
University Hospitals is World Winner for Digital Radiological Imaging Storage, Recovery Solutions
MARK YOUR CALENDARSCancer Center Seminar Series: Chasing Oncogene Addiction into the Clinic
Friday, December 16
Please join us Friday, December 16 at the next Cancer Center Seminar Series featuring Fadlo R. Khuri, MD, Deputy Director of the Winship Cancer Institute, Chair and Professor of Hematology and Medical Oncology and the Roberto C. Goizueta Distinguished Chair in Cancer Research at Emory University. Dr. Khuri will present Chasing Oncogene Addiction into the Clinic.
Dr. Khuri is an active member of the American Association for Cancer Research, American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. Dr. Khuri authored more than 180 articles for peer-reviewed journals. He serves on the editorial board for "Cancer", "Journal of Clinical Oncology", "Clinical Cancer Research", and "American Journal of Clinical Oncology", and reviews manuscripts for these and several other journals.
Dr. Khuri's research interests include development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco related cancers. His group is investigating the mechanism of action of signal transduction inhibitors in lung and head and neck cancers.
ANNOUNCEMENTSBrian Rini Kidney Cancer Drug Research Recognized in ASCO Annual Report
Research related to the AXIS 1032 study, led by Dr. Brian Rini, was featured in the American Society of Clinical Oncology (ASCO) Annual Clinical Care Advances Report, which summarizes the most important advances in clinical cancer research over the past year. Prior to this study, though there were several drugs approved to treat metastatic kidney cancer, those drugs had only been tested against placebos. This was the first trial comparing two kidney cancer drugs against each other.
Clinical Cancer Advances 2011: ASCO's Annual Report on Progress Against Cancer was published last week in the "Journal of Clinical Oncology". In this year's report, ASCO outlines 54 of the most significant advances on the front lines of cancer research over the past year, including 12 major clinical advances in such key areas as prevention and screening, personalized medicine and targeted therapies, new treatments and medications for specific diseases, reducing cancer recurrence, and more.Newly Released Treating MDS Toolkit Based on Survey Led by Mikkael Sekeres
The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to announce the launch of theTreating MDS Toolkit, a new, free resource developed for health care providers to communicate with and support their patients with myelodysplastic syndromes (MDS). The toolkit contents are based on the needs identified by MDS patients in the survey conducted by AA&MDSIF and led by Dr. Mikkael Sekeres. The survey results, which were summarized in "The Oncologist" earlier this year, showed that patients with MDS have a limited understanding of their disease characteristics, prognosis, and treatment goals, and thus may not be prepared to discuss disease-modifying therapies. Dr. Jaroslaw Maciejewski also assisted with the publication.OnCore Clinical Trials Management System Training Classes
Starting in 2012, OnCore training classes will be held quarterly. Each class will be held from 12-1 pm in Wearn 137, and will cover a different topic in the OnCore database:
The last 15-20 minutes of class will be an open session to answer specific questions. Feel free to bring your lunch. Participation is open and encouraged for anyone new or old to OnCore. One-on-one training sessions are available as needed. Contact April Firstencel (216-286-2294 firstname.lastname@example.org) with any questions.
FUNDING OPPORTUNITIESNSF Partnerships for Innovation Program
The NSF Partnerships for Innovation (PFI) program is an umbrella for two complementary subprograms: one of which involves an earlier stage that focuses on building innovation capacity and the other involves a later stage that focuses on the acceleration of innovative research. Limit of ONE application per organization.
The ASCO Resident Travel Award, funded by Susan G. Komen for the Cure®, provides financial support for residents from underrepresented populations to attend ASCO's Annual Meeting. The intention of this award is to attract residents from underrepresented populations to a possible career in one of the oncology specialties. This travel award will allow the recipients to travel to the 2012 ASCO Annual Meeting, where they will have an opportunity to meet oncologists and to understand the career possibilities in this area.
The AACR Judah Folkman Career Development Award for Antiangiogenesis Research represents a joint effort to encourage and support junior faculty who are in the first four years of a faculty appointment (at the start of the grant term) to conduct cancer research and establish successful career paths in this field.
The Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research will support highly meritorious research that is being conducted collaboratively by investigators in different countries around the world. The goals of the program are to overcome barriers to international collaboration by providing funding for costs traditional grant mechanisms may not support; raise the profile of the importance of collaboration to conquering the cancer problem; and provide the means to facilitate travel and the sharing of knowledge that otherwise may have been difficult to achieve.
The Sarcoma Foundation of America (SFA) has developed a program to provide grants to investigators interested in translational science Sarcoma research. Funding is available in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human Sarcomas. In accordance with the mission of the Foundation, research involving the development of novel agents against Sarcoma, or research that could potentially lead to the development of novel agents against Sarcoma, is eligible for this funding. Preference will be given to proposals on promising molecular targets and new or uncommon therapeutic approaches.
The Oncology Nursing Foundation is offering scholarships to registered nurses who are interested in and committed to oncology nursing to continue their education by pursuing a research doctoral degree (PhD or DNSc) or clinical doctoral degree (DNP).
The Lymphatic Research Foundation (LRF) Postdoctoral Fellowship Program is designed to support postdoctoral scientists in academic, medical or research institutions throughout the world. The awards will support investigators who have recently received their doctorates, a critical point in career development when young scientists choose their lifelong research focus. The goal of the Fellowship Program is to expand and strengthen the pool of outstanding junior investigators in the field of lymphatic research.
Ohio Cancer Research Associates has released a call for applications for research funding to support research activities broadly related to cancer and leukemia. The organization seeks to fund research that will lead to continued support at the national level.
The Childhood Brain Tumor Foundation (CBTF) is soliciting grant applications for research related to pediatric brain tumors. All proposed studies must have the approval of the proposing institution's Institutional Review Board (if appropriate) at the time of funding. Two grant applications will be selected for funding from special set-aside funds. One study will be selected for a low-grade astrocytoma/juvenile pilocytic astrocytoma and the other for Atypical Teroid/Rhabdoid Tumor.
The Irvington Institute Fellowship Program of the Cancer Research Institute, answers the need for more researchers in the field of cancer immunology. It supports qualified young scientists at leading universities and research centers around the world who wish to receive training in cancer immunology.
The Wendy Will Case Cancer Fund is accepting applications for research funding. The purpose of this fund is to support promising researchers and help them establish track records.
**All events are open to anyone interested in attending
Physiology and Biophysics Seminar
Immunology Seminar Series
Hematology and Oncology Division Research Conference
LRI Showcase Seminar
TGFβ Focus Group meeting canceled
Tumor Microenvironment and Metastasis Focus Group meeting canceled
NCRM & Stem Cell Biology and Regenerative Medicine Seminar
Special Presentation: Hematology and Oncology Research Conference
Hem/Onc Fellows Conference
Taussig Cancer Institute Grand Rounds Damir Janigro, MD
Cancer Center Seminar Series
Cancer Center Research in Progress Seminar
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
ADDITIONAL UPCOMING SEMINARS & EVENTS
PREVIOUSLY ANNOUNCED OPPORTUNITIES
AACI Translational Cancer Research Fellowship
Robert Wood Johnson Foundation Executive Nurse Fellows
NIH BULLETIN – Notices and Funding Opportunities
Collaborative HIV/AIDS Research (NOT-MH-12-011)
Pre-Application Teleconference for RFA-RM-11-022 - Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3) and RFA-RM-12-001 Stem/Progenitor Cell-Derived Human Micro-organs and -tissues (U18) (NOT-RM-12-007)
Notice of Termination of PAR-10-278, Limited Competition for the Global Research Initiative Program, Basic/Biomedical Sciences (R01) (NOT-TW-12-003)
Notice of Termination of PAR-11-037, Limited Competition: Fogarty International Research Collaboration - Basic Biomedical (FIRCA-BB) Research Award (R03) (NOT-TW-12-004)
Limited Competition: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54) (PAR-12-055)
Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])(PA-12-044)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.